These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 22651903)

  • 1. Interleukin-6 signaling pathway in targeted therapy for cancer.
    Guo Y; Xu F; Lu T; Duan Z; Zhang Z
    Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
    Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
    Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 serves as a critical factor in various cancer progression and therapy.
    Mohamed AH; Ahmed AT; Al Abdulmonem W; Bokov DO; Shafie A; Al-Hetty HRAK; Hsu CY; Alissa M; Nazir S; Jamali MC; Mudhafar M
    Med Oncol; 2024 Jun; 41(7):182. PubMed ID: 38900329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
    Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
    Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
    Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY
    Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
    Sanford DC; DeWille JW
    Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
    Ataie-Kachoie P; Pourgholami MH; Morris DL
    Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
    Nishimoto N
    Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 regulation of prostate cancer cell growth.
    Culig Z; Steiner H; Bartsch G; Hobisch A
    J Cell Biochem; 2005 Jun; 95(3):497-505. PubMed ID: 15838876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
    Trikha M; Corringham R; Klein B; Rossi JF
    Clin Cancer Res; 2003 Oct; 9(13):4653-65. PubMed ID: 14581334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
    Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
    Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
    Smith PC; Keller ET
    Prostate; 2001 Jun; 48(1):47-53. PubMed ID: 11391686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
    Matsuda T; Junicho A; Yamamoto T; Kishi H; Korkmaz K; Saatcioglu F; Fuse H; Muraguchi A
    Biochem Biophys Res Commun; 2001 Apr; 283(1):179-87. PubMed ID: 11322786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.